TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant

Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms

ASCO 2024: Lung cancer highlights

EHA 2024: Multiple myeloma roundup

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line

Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphoblastic leukaemia

More effective treatment options required for patients with MM post lenalidomide exposure

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM

Immunotherapy significantly increases the number of patients free from bowel cancer

Best practice in HRRm testing in patients with metastatic prostate cancer

ASCO 2024: Lung cancer roundup